PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Receivables growth less than half of AXSM's 23.19%. David Dodd might see more conservative credit practices, provided revenue isn't suffering.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of AXSM's 2.07%. David Dodd sees a leaner approach to short-term items.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x AXSM's -3.53%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half of AXSM's 1.11%. Michael Burry might suspect stagnation or lack of resources for expansions.
100.00%
Higher Other Assets Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-99.84%
Less than half of AXSM's 6.97%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Less than half of AXSM's 15392.73%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Revenue (Current) Growth compared to AXSM's zero value, indicating better performance.
100.00%
Exceeding 1.5x AXSM's 14.15%. Michael Burry suspects ballooning short-term obligations vs. competitor.
13.77%
Less than half of AXSM's 40.25%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Less than half of AXSM's -25.02%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
11.40%
Above 1.5x AXSM's 4.28%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.71%
Similar yoy to AXSM's -4.06%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
110.36%
Above 1.5x AXSM's 5.49%. Michael Burry suspects a significant bump in 'other' equity items vs. competitor.
-11.42%
Below half AXSM's 37.35%. Michael Burry sees potential underperformance in building shareholder capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Above 1.5x AXSM's 2.81%. Michael Burry sees a major jump. Investigate leverage rationale.
10.35%
Above 1.5x AXSM's 4.12%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.